Welcome to The Michael J. Fox Foundation's Parkinson's Disease Therapeutics Conference resources menu.
-
Conference Digital Packet
Includes the 2026 Conference Agenda, Speaker Bios and Project Abstracts.
-
Open Funding Opportunities
Learn more about the Foundation's open funding opportunities
-
Parkinson's Disease Therapeutics Pipeline Program
This program seeks to advance therapeutic development through pre-clinical and/or clinical testing of approaches addressing unmet needs of people with Parkinson’s disease (PD). The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms.
Proposals are accepted year-round on a rolling basis.
-
Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation of Research
The Alzheimer’s Association and The Michael J. Fox Foundation for Parkinson’s Research are launching the Bridge Funding for Disrupted Neurodegenerative Research (BFDN) grant program.
-
The Edmond J. Safra Fellowship in Movement Disorders
The Edmond J. Safra Fellowship in Movement Disorders aims to grow the global base of movement disorder specialists — neurologists with additional training in Parkinson's disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances.
-
-
Landscape Intelligence Reports
The Foundation’s Landscape Intelligence Reports are designed to provide a clear view of the current state and direction of Parkinson’s research and development. Each report captures a different dimension of the therapeutic and biomarker landscape—offering insights into emerging science, development progress, and MJFF’s role in advancing priority areas.
-
NEW - Biomarkers to Breakthroughs: Drug Development in the Era of Alpha-Synuclein Imaging
Published this week, this whitepaper highlights the emerging PET Trace Landscape in Parkinson’s Disease and Related Synucleinopathies.
-
Landscape of Commercial Tools for Targets to Therapies
This report provides a cursory, manually curated landscape of commercially available monoclonal antibodies, mouse models, cell lines, viral vectors, assays, and compounds for MJFF Targets to Therapies Initiative targets pursued in 2025 or under evaluation in 2026.
-
-
Advancing Targets to Therapies
Explore how MJFF’s. Targets to Therapies initiative can provide industry with the resources to evaluate emerging PD targets and inform decisions about which opportunities to advance.
-
Explore T2T Target List and Target Profiles
Review curated profiles of T2T targets, including key biological evidence, available research tools, evidence gaps, and validation plans.
-
Nominate a Target
Submit a target nomination for consideration in the T2T target list.
-
PPMI: Advancing Drug Development in Parkinson’s and Related Disorders
Learn how PPMI data, biomarkers and regulatory insights – alongside the Path to Prevention (P2P) platform trial – can inform more successful clinical trials.
-
Breakout Room Presentation
PPMI: Advancing Drug Development in Parkinson’s and Related Disorders
-
Annals of Neurology Special Issue
Review this special issue as a summary of 15+ years of PPMI, including the strategic priorities and key learnings to date
-
Partner with PPMI
In 2010, The Michael J. Fox Foundation and a core group of academic scientists and industry partners launched the Parkinson’s Progression Markers Initiative (PPMI) toward critically needed biological markers of Parkinson’s onset and progression. PPMI has since engaged thousands of partners — more sites; scientists and clinicians; industry experts; philanthropic partners; and, most importantly, study volunteers — to build a cornerstone of Parkinson’s research. Analysis from its open-access data set and available biosample library has deepened understanding of disease and informed the design of dozens of therapeutic trials.
Partner with PPMI Key Benefits Value to Industry -Connections to PPMI executive leadership and a robust ecosystem of field leaders in PD research and therapeutic development
-Closer, real-time access to emerging study data and analyses
-Representation on the PSAB to offer input on the study’s direction and strategic priorities
-Attendance at PPMI Annual Meeting each spring in NYC
-Participation in virtual study updates and dedicated working groups
-
-
MJFF Biomarker Toolkits & Resources
Explore MJFF’s biomarker toolkits and resources for measuring key PD biological pathways, and help shape how these drug development tools can better support clinical development.
-
Breakout Room Presentation
Biomarker tools to advance PD research & therapeutic development
-
LRRK2 Toolkits Information
Biomarker Recommendations for LRRK2 Therapeutic Trials in Parkinson’s Disease
-
NLRP3 Toolkits Information
Biomarker Recommendations for NLRP3 Inhibitor Trials in Parkinson’s Disease
-
GBA1 Toolkits Information
Biomarker Recommendations for GBA1 Therapeutic Trials in Parkinson’s Disease
-
-
Multimodal Data and Cohorts to Enable Precision Medicine
Learn how rapidly expanding multimodal datasets from PPMI, GP2 and other efforts can be leveraged for target discovery, patient stratification, biomarker development and trial design.
-
Breakout Room Presentation
-
AMP PD Harmonized Data | AMP-PDRD
AMP PD generates and consolidates data from eight unified cohorts (BioFIND, HBS, LBD, LCC, PDBP, PPMI, STEADY-PD3 and SURE-PD3). Data was generated using standardized technology and centrally harmonized and quality controlled. All data was generated from samples collected under similar protocols.
-
Access PPMI Data
Qualified researchers may obtain access to the full breadth of individual-level PPMI data, including clinical, imaging, ‘omics, genetic, sensor, and biomarker data.
-
-
Patient Centered Strategies for Drug Development
Learn how incorporating patient insights earlier in therapeutic development can strengthen R&D decisions, and how MJFF can help companies engage the patient community along the way.
-
Breakout Room Presentation
-
Patient Engagement Resources
We build learnings and resources to recruit and retain study participants, gather patient experience data, and connect researchers with the Parkinson’s community.
-
-
Resources For Researchers - Data, Tools, Biospecimens & More
MJFF is committed to providing support and resources to those invested in Parkinson’s research— across academia, industry, government, venture capital and more.
-
MJFF's Pre Clinical Research Tools Program
To save Researchers time and resources, MJFF makes high-quality, validated tools available to the scientific community. As of today, we have 200 tools available and another 50+ in development, spanning the following tool types including, Antibodies, Assays, Cell Models, Chemical Probes, Proteins, Plasmids, Rodent Models, and Viral Vectors.
-
Data Resources
We collaborate with the research community to collect and distribute a multitude of data resources for them to accelerate discovery and therapeutic development.
-
Biospecimen Library
MJFF makes data and biospecimens available from select Parkinson's studies for discovery and validation research.
-
Study Recruitment
MJFF invests in the infrastructure and resources to equip research teams with the tools to recruit and retain participants for their trials.
-
-
Networking and Collaboration Opportunities
The Parkinson's Disease Research Exchange (PDRx) is a global network of scientists from academic labs, pharma/biotech, CROs and investors focused on assessing the current state of Parkinson's disease research, identifying key challenges, and how to translate findings into improved therapies. In Fall 2024, MJFF launched the PDRx online platform to enhance networking and facilitate open discussion.
